Latest News and Press Releases

Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell...

NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to...

NEW YORK, 12 mai 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour...

Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial)  Pivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01...

Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01)  Analyse intermédiaire de phase 2 pivot attendue en Q4 2026Dépôt de demande d'autorisation de mise sur le...

Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a...

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...

NEW YORK, 04 mai 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa plateforme pionnière d’édition du génome pour...

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to...

NEW YORK, 27 avr. 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome...